Literature DB >> 32728990

Early detection of ventricular dysfunction by tissue Doppler echocardiography related to cardiac iron overload in patients with thalassemia.

Suchaya Silvilairat1, Pimlak Charoenkwan2, Suwit Saekho3,4, Adisak Tantiworawit5, Somdet Srichairatanakool6.   

Abstract

Cardiac T2* MRI is used as a gold standard for cardiac iron quantification in patients with transfusion-dependent thalassemia (TDT). We hypothesized that left ventricular (LV) diastolic dysfunction would reflect the severity of iron overload and can serve as an early detection of cardiac iron deposits. A study was conducted on all patients with TDT. Hemoglobin, serum ferritin and non-transferrin bound iron, together with a complete echocardiography and cardiac T2* MRI, were performed on all patients. Seventy-seven patients with TDT were enrolled (median age 14 years). In the patient group with a mean serum ferritin of > 2500 ng/mL during the past 12 months, there were more patients with severe cardiac iron deposits than in the group with a mean serum ferritin of ≤ 2500 ng/mL. Diastolic dysfunction was absent in all patients with a serum ferritin of < 1000 ng/mL. All patients with cardiac T2* ≤ 20 ms had grade III LV diastolic dysfunction. However, twenty-one percent of patients with cardiac T2* > 20 ms had LV diastolic dysfunction. The differences observed in pulmonary vein atrial reversal duration and mitral A-wave (PVAR-MVA) duration ≥ - 1 ms and an E/E' ratio ≥ 11 were proven to be the associated factors with the cardiac T2* ≤ 20 ms. Increased PVAR-MVA duration and increased E/E' ratio reliably reflected a severe iron overload, according to a cardiac T2* in patients with TDT. LV diastolic dysfunction can occur prior to severe cardiac iron deposition. Tissue Doppler echocardiography has the potential for the early detection of cardiac involvement in patients with TDT .

Entities:  

Keywords:  Cardiac T2*; Iron-overload cardiomyopathy; Non-transferrin bound iron; Tissue Doppler echocardiography; Transfusion-dependent thalassemia

Mesh:

Substances:

Year:  2020        PMID: 32728990     DOI: 10.1007/s10554-020-01949-8

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  40 in total

1.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

Authors:  L J Anderson; S Holden; B Davis; E Prescott; C C Charrier; N H Bunce; D N Firmin; B Wonke; J Porter; J M Walker; D J Pennell
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

Review 2.  Iron chelation therapy in the management of transfusion-related cardiac iron overload.

Authors:  Juliano Lara Fernandes
Journal:  Transfusion       Date:  2012-03-08       Impact factor: 3.157

Review 3.  Assessment of iron overload with T2* magnetic resonance imaging.

Authors:  Lisa J Anderson
Journal:  Prog Cardiovasc Dis       Date:  2011 Nov-Dec       Impact factor: 8.194

Review 4.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

5.  Cardiovascular MRI in thalassemia major.

Authors:  John C Wood; Leila Noetzli
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

6.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

7.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

8.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

Authors:  P Kirk; M Roughton; J B Porter; J M Walker; M A Tanner; J Patel; D Wu; J Taylor; M A Westwood; L J Anderson; D J Pennell
Journal:  Circulation       Date:  2009-10-02       Impact factor: 29.690

Review 9.  β-Thalassemia.

Authors:  Raffaella Origa
Journal:  Genet Med       Date:  2016-11-03       Impact factor: 8.822

Review 10.  Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major.

Authors:  A John Baksi; Dudley J Pennell
Journal:  Front Pharmacol       Date:  2014-09-23       Impact factor: 5.810

View more
  1 in total

1.  T2-weighted cardiovascular magnetic resonance and echocardiographic arterial elasticity criteria for monitoring cardiac siderosis in patients with beta-thalassemia major.

Authors:  Reihaneh Zavar; Moien Hendimarjan; Mohaddeseh Behjati; Dalir Yazdani
Journal:  J Res Med Sci       Date:  2022-06-30       Impact factor: 1.985

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.